文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

初治HIV-1感染者中多拉韦林耐药相关突变罕见

Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

该研究分析了2010至2016年希腊、意大利和法国9764例初治HIV-1感染者的NNRTI耐药突变,发现多拉韦林耐药相关突变总体患病率仅1.4%,K103N/Y181C为0.05%,远低于其他NNRTI耐药突变,支持多拉韦林用于初治患者。

要点

  • 初治患者多拉韦林耐药相关突变患病率1.4%,K103N/Y181C仅0.05%。
  • B与非B亚型间多拉韦林耐药突变频率相似。
  • 利匹韦林、依曲韦林、奈韦拉平和依非韦伦耐药患病率均更高。

核心结论

  • 初治HIV-1感染者中多拉韦林耐药相关突变患病率很低,支持多拉韦林用于初治患者。

研究设计与样本

  • 2010至2016年在希腊、意大利和法国对9764例初治患者用批量测序检测NNRTI耐药。

主要发现

  • 至少一种多拉韦林耐药相关突变者137例(1.4%),K103N/Y181C者5例(0.05%)。
  • 最常见突变为V108I(62例,0.6%)、Y318F(23例,0.2%)、Y188L(18例,0.2%)和H221Y(18例,0.2%)。
  • 多拉韦林耐药突变频率在B与非B亚型间相似。
  • 利匹韦林、依曲韦林、奈韦拉平和依非韦伦耐药患病率按ANRS算法分别为8.5%、8.1%、8.3%和3.9%,按Stanford算法分别为9.9%、10.0%、7.5%和9.4%。

临床怎么用

  • 初治患者启动多拉韦林方案前耐药突变风险低,但仍需结合当地流行株和耐药检测结果综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Doravirine is a novel HIV-1 NNRTI recently shown to be non-inferior to both darunavir/ritonavir and efavirenz in combination therapy with two NRTIs in treatment-naive patients. Doravirine has an in vitro resistance profile that is distinct from other NNRTIs and retains activity against viruses containing the most frequently transmitted NNRTI mutations. OBJECTIVES: The aim of this study was to examine the prevalence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients in Europe. METHODS: From 2010 to 2016, 9764 treatment-naive patients were tested for NNRTI antiretroviral drug resistance by bulk sequencing in Greece, Italy and France. We studied the prevalence of doravirine resistance-associated mutations previously identified in vitro: V106A/M, V108I, Y188L, V190S, H221Y, F227C/L/V, M230I/L, L234I, P236L, Y318F and K103N/Y181C. RESULTS: Among 9764 sequences, 53.0% and 47.0% of patients had B and non-B subtypes, respectively. Overall, the presence of at least one doravirine resistance-associated mutation (n = 137; 1.4%) or the K103N/Y181C mutations (n = 5; 0.05%) was very rare. The most prevalent mutations were V108I (n = 62; 0.6%), Y188L (n = 18; 0.2%), H221Y (n = 18; 0.2%) and Y318F (n = 23; 0.2%). The frequency of doravirine resistance-associated mutations was similar between B and non-B subtypes. In comparison, the prevalence of rilpivirine, etravirine, nevirapine and efavirenz resistance was higher whatever algorithm was used (ANRS: 8.5%, 8.1%, 8.3% and 3.9%, respectively; Stanford: 9.9%, 10.0%, 7.5% and 9.4%, respectively). CONCLUSIONS: The prevalence of doravirine resistance-associated mutations is very low in antiretroviral-naive patients. These results are very reassuring for doravirine use in naive patients.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Soulie C, Santoro MM, Charpentier C, et al. Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients. J Antimicrob Chemother. 2019. PMID: 30476106. doi:10.1093/jac/dky464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。